DIA
Drug Information Association Logo
« Back to Listing

How Can Studies that Inform Relative Effectiveness Best Be Incorporated into Global Drug Development Plans?

Track:
Comparative Effectiveness Research/Global Health Outcomes and Economics

Day & Time:
June 19, 10:45AM - 12:15PM (Pacific Standard Time)

Session Number:
422

Room Number:
7B

Level:
Intermediate

Type:
Forum

Title:
How Can Studies that Inform Relative Effectiveness Best Be Incorporated into Global Drug Development Plans?

Chair(s):
Chris Chinn
Vice President, Real World Data, Value Evidence and Outcomes Group, R&D
GlaxoSmithKline UK Ltd., United Kingdom

Description:
GetReal, an EU Innovative Medicines Initiative (IMI) public-private partnership composed of pharmaceutical companies, academia, health technology assessment (HTA) agencies, and regulators, will host a discussion on ways of incorporating relative effectiveness objectives into pre-authorization development, and the implications for international HTA, regulatory, and drug development decision-making.

Learning Objective(s):
Recognize the regulatory, health technology assessment (HTA), and operational challenges facing the implementation of alternative drug development strategies prior to medicine authorization; Explain how global drug development plans can better incorporate relative effectiveness objectives, real-world data, and analytical techniques prior to medicine authorization.

Presentation(s) & Speaker(s):
Panelist
Chris Chinn
Vice President, Real World Data, Value Evidence and Outcomes Group, R&D
GlaxoSmithKline UK Ltd., United Kingdom

Panelist
Mark Trusheim, MSc
Executive in Residence and Visiting Scientist
Massachusetts Institute of Technology, Sloan School of Management, United States